Artigos com autorizações de acesso público - Ulrika SH SimonssonSaiba mais
Não disponível em nenhum local: 1
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 …
D Röshammar, USH Simonsson, H Ekvall, L Flamholc, V Ormaasen, ...
Journal of pharmacokinetics and pharmacodynamics 38 (6), 727-742, 2011
Autorizações: Swedish Research Council
Disponíveis em algum local: 60
A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses
RJ Svensson, RE Aarnoutse, AH Diacon, R Dawson, SH Gillespie, ...
Clinical Pharmacology & Therapeutics 103 (4), 674-683, 2018
Autorizações: Bill & Melinda Gates Foundation, Swedish Research Council
A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions
SG Wicha, C Chen, O Clewe, USH Simonsson
Nature communications 8 (1), 1-11, 2017
Autorizações: Swedish Research Council
The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis
EM Svensson, RJ Svensson, LHM Te Brake, MJ Boeree, N Heinrich, ...
Clinical Infectious Diseases 67 (1), 34-41, 2018
Autorizações: Federal Ministry of Education and Research, Germany
Population pharmacokinetics of ethambutol in South African tuberculosis patients
S Jönsson, A Davidse, J Wilkins, JS Van der Walt, USH Simonsson, ...
Antimicrobial agents and chemotherapy 55 (9), 4230-4237, 2011
Autorizações: US National Institutes of Health
Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses
SP Zvada, P Denti, PR Donald, HS Schaaf, S Thee, JA Seddon, HI Seifart, ...
Journal of Antimicrobial Chemotherapy 69 (5), 1339-1349, 2014
Autorizações: US National Institutes of Health, Wellcome Trust
Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial
CM Upton, RC van Wijk, L Mockeliunas, USH Simonsson, K McHarry, ...
EClinicalMedicine 48, 101414, 2022
Autorizações: Swedish Research Council, European & Developing Countries Clinical Trials …
Greater Early Bactericidal Activity at Higher Rifampicin doses Revealed by Modeling and Clinical Trial Simulations
RJ Svensson, EM Svensson, RE Aarnoutse, AH Diacon, R Dawson, ...
The Journal of Infectious Diseases, 2018
Autorizações: Bill & Melinda Gates Foundation, Swedish Research Council
A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro
O Clewe, L Aulin, Y Hu, ARM Coates, USH Simonsson
Journal of Antimicrobial Chemotherapy 71 (4), 964-974, 2015
Autorizações: Swedish Research Council
Machine learning and pharmacometrics for prediction of pharmacokinetic data: differences, similarities and challenges illustrated with rifampicin
L Keutzer, H You, A Farnoud, J Nyberg, SG Wicha, G Maher-Edwards, ...
Pharmaceutics 14 (8), 1530, 2022
Autorizações: Swedish Research Council, European Commission, Federal Ministry of Education …
Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients
SP Zvada, P Denti, FA Sirgel, E Chigutsa, M Hatherill, S Charalambous, ...
Antimicrobial agents and chemotherapy 58 (1), 503-510, 2014
Autorizações: US National Institutes of Health, Wellcome Trust
The implications of model-informed drug discovery and development for tuberculosis
M Muliaditan, GR Davies, USH Simonsson, SH Gillespie, O Della Pasqua
Drug Discovery Today 22 (3), 481-486, 2017
Autorizações: UK Medical Research Council
Application of the multistate tuberculosis pharmacometric model in patients with rifampicin‐treated pulmonary tuberculosis
RJ Svensson, USH Simonsson
CPT: pharmacometrics & systems pharmacology 5 (5), 264-273, 2016
Autorizações: Swedish Research Council
Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
C Zhang, H Mcllleron, Y Ren, JS van der Walt, MO Karlsson, ...
Antiviral therapy 17 (1), 25, 2012
Autorizações: US National Institutes of Health
Forecasting clinical dose–response from preclinical studies in tuberculosis research: translational predictions with rifampicin
SG Wicha, O Clewe, RJ Svensson, SH Gillespie, Y Hu, ARM Coates, ...
Clinical Pharmacology & Therapeutics 104 (6), 1208-1218, 2018
Autorizações: Swedish Research Council
Early bactericidal activity of meropenem plus clavulanate (with or without rifampin) for tuberculosis: the COMRADE randomized, phase 2A clinical trial
V De Jager, N Gupte, S Nunes, GL Barnes, RC van Wijk, J Mostert, ...
American journal of respiratory and critical care medicine 205 (10), 1228-1235, 2022
Autorizações: US National Institutes of Health, Swedish Research Council
Assessing Pharmacodynamic Interactions in Mice using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models
C Chen, SG Wicha, GJ de Knegt, F Ortega, L Alameda, V Sousa, ...
CPT: Pharmacometrics & Systems Pharmacology, 2017
Autorizações: Swedish Research Council
The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model
C Chen, F Ortega, J Rullas, L Alameda, I Angulo-Barturen, S Ferrer, ...
Journal of Pharmacokinetics and Pharmacodynamics 44 (2), 133-141, 2017
Autorizações: Swedish Research Council
A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations
O Clewe, SG Wicha, CP de Vogel, JEM de Steenwinkel, USH Simonsson
Journal of Antimicrobial Chemotherapy 73 (2), 437-447, 2017
Autorizações: Swedish Research Council
Clinical standards for the management of adverse effects during treatment for TB
KP Singh, ACC Carvalho, R Centis, GB Migliori, SG Mpagama, ...
The International Journal of Tuberculosis and Lung Disease 27 (7), 506-519, 2023
Autorizações: US National Institutes of Health, Government of Italy
As informações de publicação e financiamento são determinadas automaticamente por um programa informático.